May 2024 in “Deleted Journal” This study reports that chemotherapy-induced hair loss affects up to 65% of patients, typically within 1 to 3 weeks of treatment, while scalp cooling may help prevent severe hair loss with taxane-based therapies.
26 citations
,
October 2018 in “Clinical & Translational Oncology” This review outlines dermatological toxicities associated with targeted cancer therapies and immunotherapies, emphasizing the need for collaborative management by oncologists and dermatologists but reports no new clinical findings.
179 citations
,
October 2018 in “American Journal of Clinical Dermatology” This review outlines various dermatologic adverse events associated with targeted therapies and immunotherapies, emphasizing the need for collaboration between dermatologists and oncologists to manage these effects effectively; it reports no new clinical findings.
1 citations
,
January 2024 in “ACS Medicinal Chemistry Letters” This Patent Highlight discusses recent progress in developing TYK2 inhibitors, which show potential for treating conditions like cancer, alopecia areata, and psoriatic arthritis.
278 citations
,
May 2013 in “Ca” This review discusses the shift in toxicity profiles of cancer therapies from traditional chemotherapy to targeted agents, noting similar overall toxicities but with different side effects, and reports no new findings.